The Medicines Co (MDCO)

33.37
1.17 3.39
NASDAQ : Health Care
Prev Close 34.54
Open 34.03
Day Low/High 32.29 / 34.50
52 Wk Low/High 27.50 / 43.79
Volume 1.32M
Avg Volume 1.35M
Exchange NASDAQ
Shares Outstanding 70.79M
Market Cap 2.44B
EPS -5.30
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

The Medicines Company To Host Conference Call And Webcast To Review Data From Ongoing ORION-1 Phase 2 Study Of PCSK9si

The Medicines Company To Host Conference Call And Webcast To Review Data From Ongoing ORION-1 Phase 2 Study Of PCSK9si

The Medicines Company (NASDAQ: MDCO) will host a conference call and webcast on Tuesday, November 15, 2016, at 3:00 p.

The Medicines Company Discontinues Development Of MDCO-216, Its Investigational Cholesterol Efflux Promoter

The Medicines Company Discontinues Development Of MDCO-216, Its Investigational Cholesterol Efflux Promoter

The Medicines Company (NASDAQ:MDCO) announced today the immediate discontinuation of the clinical development program for MDCO-216, its investigational cholesterol efflux promoter.

The Medicines Company Reports Third-Quarter 2016 Financial Results

The Medicines Company Reports Third-Quarter 2016 Financial Results

The Medicines Company (NASDAQ:MDCO) today announced its financial results for the third quarter ended September 30, 2016.

The Medicines Company Announces Positive Top-Line Results From Day 90 Interim Analysis In Ongoing ORION-1 Phase 2 Study Of PCSK9si

The Medicines Company Announces Positive Top-Line Results From Day 90 Interim Analysis In Ongoing ORION-1 Phase 2 Study Of PCSK9si

The Medicines Company (NASDAQ:MDCO) today announced top-line results from the interim analysis with Day 90 follow-up for all 501 patients enrolled in the ongoing ORION-1 study of PCSK9si, its investigational first-in-class...

The Medicines Company To Announce Third Quarter Financial Results On October 26, 2016

The Medicines Company To Announce Third Quarter Financial Results On October 26, 2016

The Medicines Company (NASDAQ:MDCO) has scheduled its quarterly conference call for October 26, 2016 at 8:30 a.

The Medicines Company's Infectious Disease Portfolio Featured In 16 Presentations At IDWeek 2016

The Medicines Company's Infectious Disease Portfolio Featured In 16 Presentations At IDWeek 2016

The Medicines Company (NASDAQ:MDCO) today announced that data from its portfolio of antimicrobial products and product candidates will be featured in 16 presentations at IDWeek 2016, to be held October 26-30,...

The Medicines Company To Present Data From Its Investigational Anesthetic MDCO-700 At The ANESTHESIOLOGY® 2016 Annual Meeting And The ISAP 25th Annual Meeting

The Medicines Company To Present Data From Its Investigational Anesthetic MDCO-700 At The ANESTHESIOLOGY® 2016 Annual Meeting And The ISAP 25th Annual Meeting

The Medicines Company (NASDAQ:MDCO) today announced that five abstracts with data from its investigational anesthetic MDCO-700 (formerly, ABP-700) development program will be presented at ANESTHESIOLOGY® 2016,...

Why Medicines Co. (MDCO) Stock is Falling Today

Why Medicines Co. (MDCO) Stock is Falling Today

Medicines Co. (MDCO) stock is under pressure today because its drug development partner Alnylam Pharmaceuticals (ALNY) ended testing on one of its gene-silencing treatments.

The Medicines Company Provides Progress Update On Ongoing ORION-1 Study Of PCSK9si

The Medicines Company Provides Progress Update On Ongoing ORION-1 Study Of PCSK9si

The Medicines Company (NASDAQ:MDCO) today provided a progress update on the ongoing ORION-1 study of PCSK9si, its investigational first-in-class PCSK9 synthesis inhibitor.

Notable Wednesday Option Activity: MDCO, PEIX, BEAT

Notable Wednesday Option Activity: MDCO, PEIX, BEAT

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Medicines Co , where a total volume of 4,663 contracts has been traded thus far today, a contract volume which is representative of approximately 466,300 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 57.9% of MDCO's average daily trading volume over the past month, of 805,825 shares.

The Medicines Company Awarded Up To $132 Million To Develop Portfolio Of New Antibiotics Targeting Drug-Resistant Infections Under Strategic Partnership With BARDA

The Medicines Company Awarded Up To $132 Million To Develop Portfolio Of New Antibiotics Targeting Drug-Resistant Infections Under Strategic Partnership With BARDA

The Medicines Company (NASDAQ:MDCO) today announced that it has entered into a new strategic partnership with the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant...

The Medicines Company Provides Update On Dyslipidemia Programs

The Medicines Company Provides Update On Dyslipidemia Programs

The Medicines Company (NASDAQ:MDCO) today provided an update on its clinical dyslipidemia research programs for MDCO-216 (which contains APoA-1 Milano) and PCSK9si (PCSK9 synthesis inhibitor).

The Medicines Company Reports Second-Quarter 2016 Business And Financial Results

The Medicines Company Reports Second-Quarter 2016 Business And Financial Results

The Medicines Company (NASDAQ:MDCO) today announced its business and financial results for the second quarter ended June 30, 2016.

The Medicines Company To Announce Second Quarter Financial Results On July 27, 2016

The Medicines Company To Announce Second Quarter Financial Results On July 27, 2016

The Medicines Company (NASDAQ:MDCO) has scheduled its quarterly conference call for July 27, 2016 at 8:30 a.

Federal Circuit Rules For The Medicines Company In Angiomax® (bivalirudin) Patent Litigation

Federal Circuit Rules For The Medicines Company In Angiomax® (bivalirudin) Patent Litigation

The Medicines Company announced that the U.S.

Barbarian At The Gate: Medicines (MDCO)

Barbarian At The Gate: Medicines (MDCO)

Trade-Ideas LLC identified Medicines (MDCO) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate

Medicines (MDCO) Flagged As Strong On High Volume

Medicines (MDCO) Flagged As Strong On High Volume

Trade-Ideas LLC identified Medicines (MDCO) as a strong on high relative volume candidate

The Medicines Company Announces Positive Top- Line Results For Phase 3 TANGO 1 Clinical Trial Of CARBAVANCE®

The Medicines Company Announces Positive Top- Line Results For Phase 3 TANGO 1 Clinical Trial Of CARBAVANCE®

The Medicines Company (NASDAQ:MDCO) today announced that its investigational antibiotic, CARBAVANCE ® (meropenem-vaborbactam), met both FDA and EMA pre-specified primary endpoints in the Phase 3 TANGO 1 clinical trial...

The Medicines Company Completes Divestiture Of Its Non-Core Cardiovascular Assets To Chiesi

The Medicines Company Completes Divestiture Of Its Non-Core Cardiovascular Assets To Chiesi

The Medicines Company (NASDAQ:MDCO) today announced the completion of the previously-disclosed divestiture of its non-core cardiovascular assets, Cleviprex® (clevidipine) injectable emulsion, Kengreal® (cangrelor)...

Insiders Are Scooping Up Shares of These 5 Stocks

Insiders Are Scooping Up Shares of These 5 Stocks

Here's a technical look at how to trade five stocks that have seen recent insider buying.

The Medicines Company Announces Initiation Of Phase II Study For Its Investigational Anesthetic, ABP-700

The Medicines Company Announces Initiation Of Phase II Study For Its Investigational Anesthetic, ABP-700

The Medicines Company announced today that it has dosed the first patient in a Phase II study of ABP-700 in procedural sedation.

The Medicines Company Announces Participation At ASM MICROBE 2016 To Be Held June 16 - 20 In Boston

The Medicines Company Announces Participation At ASM MICROBE 2016 To Be Held June 16 - 20 In Boston

The Medicines Company (NASDAQ:MDCO) today announced that 11 presentations on its infectious disease programs will be presented at the first annual ASM Microbe 2016 to be held June 16-20 in Boston, MA.

MDCO: Insiders vs. Shorts

MDCO: Insiders vs. Shorts

The most recent short interest data was recently released for the 03/31/2016 settlement date, and Medicines Co is one of the most shorted stocks of the Russell 3000, based on 13.02 "days to cover" versus the median component at 5.75. There are a number of ways to look at short data, but one metric that we find particularly useful is the "days to cover" because it considers both the total shares short and the average daily volume of shares typically traded.

Medicines (MDCO) Moving On Heavy Pre-Market Trading

Medicines (MDCO) Moving On Heavy Pre-Market Trading

Trade-Ideas LLC identified Medicines (MDCO) as a pre-market mover with heavy volume candidate

The Medicines Company Prices $350 Million Of Convertible Notes

The Medicines Company Prices $350 Million Of Convertible Notes

The Medicines Company (NASDAQ:MDCO) (the "Company") today announced that it has priced its private offering of $350 million in aggregate principal amount of its convertible senior notes due 2023.

Barbarian At The Gate: Medicines (MDCO)

Barbarian At The Gate: Medicines (MDCO)

Trade-Ideas LLC identified Medicines (MDCO) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate

The Medicines Company Announces Intention To Offer $350 Million Of Convertible Notes

The Medicines Company Announces Intention To Offer $350 Million Of Convertible Notes

The Medicines Company (NASDAQ:MDCO) (the "Company") today announced that it proposes to offer $350 million aggregate principal amount of convertible senior notes due 2023, subject to market conditions and other factors.

The Medicines Company Completes Patient Enrollment For ORION-1 Study Of PCSK9si

The Medicines Company Completes Patient Enrollment For ORION-1 Study Of PCSK9si

The Medicines Company (NASDAQ:MDCO) has announced the completion of patient enrollment in the ORION-1 study of PCSK9si, its investigational first-in-class RNA interference (RNAi) proprotein convertase subtilisin/kexin type...